MedImmune, the R&D department of pharma giant AstraZeneca, has licensed the rights to develop and test cancer-fighting drugs to Yale spin-out Koltan Pharmaceuticals. Spun out of the University’s School of Medicine in 2007, the US-based life sciences firm Koltan intends to develop the drug, which has been designed to target a receptor connected to cancers…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
